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ABSTRACT 
A simple, rapid, precise, rapid, sensitive and reproducible reverse phase high performance liquid 
chromatographic (RP-HPLC) method has been developed for quantitative analysis of Telmisartan 
(TELM) in pharmaceutical dosage forms. Chromatographic separation of TELM and its degradation 
products was achieved on a C18, 250 × 4.6 mm, 5µ, Waters symmetry column.  The flow rate was 1.0 
ml/min, the column temperature 400C, and detection was by absorption at 230 nm using a photodiode 
array detector. The number of theoretical plates and tailing factor for TELM were 8,721 and 1.018, 
respectively. TELM was exposed to thermal, photolytic, hydrolytic (acidic and alkali), and oxidative 
stress, and the stressed samples were analyzed by use of the proposed method. Peak homogeneity data 
for TELM in the chromatograms from the stressed samples, obtained by use of the photodiode-array 
detector, demonstrated the specificity of the method for analysis of TELM in the presence of the 
degradation products. The linearity of the method was excellent over the range 10–50 µg/ml. The 
correlation coefficient was 0.999. Relative standard deviations of peak areas of all measurements were 
always less than 2%. The proposed method was found to be suitable and accurate for quantitative 
analysis of TELM and study of its stability. 
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1.  Introduction: 
Telmisartan (TELM) chemically described as 
4[(1,4‐dimethyl‐2‐propyl(2,6‐bi‐1H‐ 
benzimidazol]‐1‐yl)methyl][1,1‐biphenyl]‐2‐ 
carboxylic acid (fig. 1) is a potent, long‐lasting, 
nonpeptide antagonist of the angiotensin II 
(AT1) receptor that is indicated for the treatment 
of essential hypertension. It selectively and 
insurmountably inhibits stimulation of the AT1 
receptor by angiotensin II without affecting 
other receptor systems involved in 
cardiovascular regulation. In clinical studies, 
TELM shows comparable antihypertensive 
activity to other major antihypertensive classes, 
such as angiotensin converting enzyme (ACE) 
inhibitors, beta‐blockers and calcium 
antagonists1, 2. 
Literature review revealed that there are various 
methods for determination of Telmisartan, 
individually and in combination with other 
drugs. A variety of analytical methods for 
estimation of Telmisartan are previously 
reported. The majority of methods reported are 
liquid chromatography coupled to UV, tendem 
mass spectrometry or mass spectrometry 
detection but some determinations were also 
performed by thin layer, ratio derivative 
spectrophotometry and spectrofluorimetry. 
Individually, Telmisartan is estimated by LC-
MS 3, LC-tendem MS4, 5. The majority of 
methods reported are liquid chromatography in 
which Telmisartan was estimated 
simultaneously with hydrochlorthiazide 6, 7, 8, 
with ramipril 9, 10, with Amlodipine11. Some 
triple combinations are also reported along with 
telmisartan such as, Column Switching LC with 
fluorescence detection12. Some HPTLC methods 
are also reported for estimation of Telmisartan 
along with other drugs13, 14, 15. None of these 
analytical procedures has been described as a 
stability-indicating method for analysis of 
TELM in the presence of its degradation 
products. 
 
2. Experimental: 
a. Chemicals: Telmisartan (99.4%) was 
obtained from Cipla Pharmaceutical Ltd, 
Mumbai, India, as gift samples. Acetonitrile 
(HPLC Grade), Methanol (HPLC Grade), 
Potassium dihydrogen phosphate (AR Grade), 
ortho‐phosphoric acid (AR Grade) were 
purchased from E. Merck (India) Ltd. The 
0.45‐µm nylon filters were purchased from 
Advanced Micro Devices Pvt. Ltd. Chandigarh, 
India. Mili‐Q water was used throughout the 
experiment. Tablets were purchased from Indian 
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market containing of Telmisartan 40 mg per 
tablet. 
b. Instruments: Analysis was performed on a 
chromatographic system Agilent 1200 series 
separation module (Japan) equipped with an 
auto injector (G1329A), Diode array detector SL 
(G1315C), Quaternary pump (G1311A) and 
column thermostat (G1316A). Data acquisition 
was made with Chemstation software. The peak 
purity was evaluated with DAD detector. 
c. Liquid chromatographic conditions: 
Chromatographic conditions were obtained 
using a stainless steel column (Waters symmetry 
C18 250mm x 4.6mm 5µm), which was 
maintained at 40⁰C. The analytical wavelength 
was set at 230 nm and samples of 60 µl were 
injected to HPLC system. The mobile phase was 
Potassium dihydrogen phosphate (10mM, pH 
3.0 adjusted with ortho‐phosphoric acid) and 
acetonitrile in ratio of 60:40 (v/v) to 70:30 (v/v) 
at a flow rate of 1ml/min. The mobile phase was 
filtered through 0.45µm filter and degassed for 
10 minutes by sonication. For analysis of 
samples obtained by forced degradation, the 
photodiode-array detector was used in scan 
mode in the range 200–400 nm. Peak 
homogeneity was expressed as peak purity and 
was obtained directly from the spectral analysis 
report by use of the above-mentioned 
software16,17. 
d. Standard solutions: 
1. Stock standard solutions:  An accurately 
weighed quantity of 10 mg of Telmisartan 
was transferred into a 100 ml volumetric 
flask. Dissolved with 30 ml of methanol 
and diluted to required volume with mobile 
phase, having the concentration of 100 
µg/ml of Telmisartan.  
2. Preparation of working standard: From 
the standard stock solution 10 ml is pipette 
out into 100 ml volumetric flask and made 
up the volume with mobile phase, having 
the concentration of 10 µg/ml of 
Telmisartan18. 
e. Procedure for Forced Degradation Study: 
Stability testing is an important part of the 
process of drug product development. The 
purpose of stability testing is to provide 
evidence of how the quality of a drug substance 
or drug product varies with time under a variety 
of environmental conditions, for example 
temperature, humidity, and light, and enables 
recommendation of storage conditions, retest 
periods, and shelf life to be established. The two 
main aspects of drug product that play an 
important role in shelf-life determination are 
assay of the active drug and the degradation 
products generated during stability studies. The 
objective of this work was to develop an 
analytical LC procedure which would serve as a 
stability-indicating method for assay of TELM 
drug product. Forced degradation of the drug 
product was carried out under thermolytic, 
photolytic, acid/base hydrolytic, and oxidative 
stress conditions. Forced degradation of the drug 
products under acidic, basic, and oxidizing 
conditions was performed using centrifuged and 
filtered solution (as described in the section 
‘‘Preparation of Sample Solution’’) containing 
10 µg/ml TELM. For thermolytic and photolytic 
degradation, a quantity of powder equivalent to 
10 mg TELM was exposed19.  
Acidic Degradation: Centrifuged sample stock 
solution (1 ml) was transferred to a 10 ml 
volumetric flask and 3 ml 1 M HCl was added. 
The mixture was left at 60 0C for 8 h in a water 
bath then left to equilibrate to ambient 
temperature, then diluted to 10 ml with diluent. 
Alkaline Degradation: Centrifuged sample 
stock solution (1 ml) was transferred to a 10 ml 
volumetric flask and 3 ml 0.01 M NaOH was 
added. The mixture was left for 10 min at 
ambient temperature, then diluted to 10 ml with 
diluent. 
Oxidative Degradation: Centrifuged sample 
stock solution (1 ml) was transferred to a 10 ml 
volumetric flask and 3 ml 30% H2O2 was added. 
The mixture was left for 2 h at ambient 
temperature then diluted to 10 ml with diluent. 
Thermal Degradation: Approximately 250 mg 
drug product powder was left at 300C, 400C, 
500C for 1 month. The sample was then treated 
to obtain solution containing 10 µg/ ml TELM. 
UV Degradation: Approximately 250 mg drug 
product powder was exposed to short-
wavelength UV light for 24 h. The sample was 
then treated to obtain solution containing 10 µg/ 
ml TELM20,21,22. 
 
3. Results and Discussion: 
Optimization of the chromatographic 
conditions 
Column                        :  Waters symmetry, ODS 
C18; 4.6 x 150 mm, 5microns 
Mobile Phase             :  10 mM pot. Di hydrogen 
phosphate: Acetonitrile (60:40)   
                                       gradient method. 
pH                               :  3.0 ±0.01 
Flow rate                     :  1 ml/min 
Detector                  :  UV 
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Injection volume       :  60µl 
Column temperature :  Ambient 
Wavelength                 :  230 nm 
Run time                  :  70 minutes. 
 
Chromatographic separation of TELM from its 
degradation products was achieved on Waters 
symmetry, ODS C18; 4.6 x 150 mm, 5microns. 
Development studies revealed that pot. Di 
hydrogen phosphate: Acetonitrile (60:40)  was 
used which vary to (70:30 v/v) (gradient 
method) at a flow rate of 1.0 ml/min and a 
column temperature of 400C were suitable 
conditions for a stability-indicating method for 
study of the degradation of TELM. TELM peak 
shape was good, with little tailing, and TELM 
was well resolved from its degradation products. 
The retention time of TELM was, typically, 
approximately 28.82 min and chromatographic 
analysis time was than 70 min. Under the 
optimized conditions TELM and its degradation 
products were well separated. 
Although the conditions used for forced 
degradation were attenuated to achieve 
degradation in the range 10–30%, this could not 
be achieved for thermal and photolytic 
degradation even after prolonged exposure. 
During the initial forced degradation 
experiments it was observed that alkaline 
hydrolysis of TELM was a rapid reaction the 
drug was extensively degraded by alkali 
hydrolysis, thermal and oxidative condition. 
Table 1 indicates the extent of degradation, and 
assay of TELM under the various stress 
conditions.  Chromatograms obtained from 
TELM tablet solution, and solutions after acidic 
and alkaline hydrolysis and oxidative 
degradation of the drug product are shown in 
Fig. 2 &3, respectively. 
 
Conclusion: 
In this study, a selective and validated stability-
indicating HPLC assay method for Telmisartan 
was developed, which could separate the drug 
and its degradation products formed under a 
variety of stress conditions. 
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Figures : 
Fig. 1 Structure of Telmisartan 
 
 
Fig. 2 Thermal degradation of tab sample at 40 oC temp.  
  
 
 
Fig. 3 Thermal degradation of tab sample at 50 oC temp. 
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TABLES 
Table 1 Results of forced degradation study 
 
Stress condition Degradation % of 
TELM 
% Assay 
Thermal Stress 30 0C 3.16 96.84 
 40 0C 7.88 92.12 
 50 0C 18.64 81.36 
Alkaline stress 0.1 N NaOH, 8h 8.8 91.20 
 1 N NaOH, 12h 27.84 72.16 
 2 N NaOH, 24h 38.29 61.71 
Oxidative stress 3 %, 6 h No Degradation 99.28 
 3 %, 24 h No Degradation 99.18 
 10 %, 24 h 3.18 96.88 
Acidic stress 0.1 N HCl / 8 h No Degradation 99.28 
 1 N HCl / 12 h No Degradation 99.25 
 2 N HCl / 24 h No Degradation 99.25 
 5 N HCl / 24 h No Degradation 99.19 
UV stress 1.2×106 Lux hours No Degradation 99.18 
 6×106 Lux hours No Degradation 99.19 
 
